Biomarker Assay Development
Whether you develop biomarker assays for use in clinical trials, market approved diagnostics/prognostics,
or phase IV pharmacovigilance, Cambridge Biomedical can help meet your goals.
We work with small and large molecules and medical devices. We have experience with a wide range
of projects, from de novo test development to technology transfer engagements where the target and
reagents are developed but require optimization and assay validation.
Our specific areas of expertise include: de novo assay development, assay technology transfer, optimization and validation of novel or commercially available kits. We work with biological matrices from humans or animals as well as both small and large therapeutic molecules.
Our development capabilities are supported by a CLIA certified, CAP accredited laboratory capable
of processing 10 or 10,000 samples.
Methods and Technologies
We seamlessly adapt to your needs, bringing experience with most assay development methods and technologies including:
PCR, ELISA, MSD, RIA, HPLC, cell based assays, IHC, Luminex®, and flow cytometry.
Our technicians average eight years' experience in their platform specializations, assuring your organization of the highest level laboratory work.